Genmab achieves USD 45 million milestone
Milestone triggered by first commercial sale of DARZALEX in the United States
"Today marks a significant moment in the history of Genmab - the day DARZALEX, our second approved antibody therapeutic, is commercially available. We are very pleased to have brought two differentiated antibody products to the market since our inception in 1999," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
This milestone was included in the updated financial guidance for 2015, which was published on November 16, 2015.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.